Patients Given Sunitinib Need Close Monitoring For Cardiac Problems

December 17th, 2007 | Category: Cancer

Sunitinib-a tyrosine-kinase inhibitor used to extend survival in patients with renal-cell carcinoma and gastrointestinal stromal tumours-has cardiotoxic effects. As such, patients given sunitinib, particularly those with cardiac risk factors-need to be closely monitored. These are

the conclusions of authors of an write-up published in that week’s edition of The Lancet. [click link for full article]

Original post by Women’s Health / Gynecology News From Medical News Today

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • BlinkList
  • Furl
  • IndianPad
  • Netscape
  • Reddit
  • Simpy
  • Spurl
  • StumbleUpon
  • Technorati
Related Articles
  • Sunitinib May Slow Growth And Spread Of Liver Cancer
  • Another “Smart” Cancer Drug Can Have Toxic Effects On The Heart
  • Safety And Efficacy Of Sunitinib In An Expanded-Access Trial Of Metastatic Renal Cell Carcinoma (mRCC)
  • Beyond The Abstract - Pathological Evidence Of Necrosis In Recurrent Renal Mass Following Treatment With Sunitinib
  • Management Guidelines For Patients On Sunitinib

    • No comments yet. Be the first.

    Leave a reply

    You must be logged in to post a comment.